| Edith Short, | |
|
484 Stony Kill Rd, Accord, NY 12404-5432 | |
| (845) 389-9449 | |
| (845) 331-8427 |
| Full Name | Edith Short |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 484 Stony Kill Rd, Accord, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861919441 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 637444 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Edith Short, 484 Stony Kill Rd, Accord, NY 12404-5432 Ph: (845) 389-9449 | Edith Short, 484 Stony Kill Rd, Accord, NY 12404-5432 Ph: (845) 389-9449 |
News Archive
Dying in America is an expensive process, with about one in four Medicare dollars going to care for people in their last year of life. But for African Americans and Hispanics, the cost of dying is far higher than it is for whites.
A previously unknown link between the immune system and the death of motor neurons in Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, has been discovered by scientists at the CHUM Research Centre and the University of Montreal. The finding paves the way to a whole new approach for finding a drug that can cure or at least slow the progression of such neurodegenerative diseases as ALS, Alzheimer's, Parkinson's and Huntington's diseases.
People who spend more time in the sun and those with higher vitamin D levels may be less likely to develop multiple sclerosis (MS), according to a study published in the February 8, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology. MS is a chronic disease of the brain and spinal cord, usually with recurrent flare-ups of symptoms. It is often preceded by a first episode (or event) of similar symptoms lasting days to weeks.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).
› Verified 6 days ago
Alyssa Kane O'donnell, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 122 Kyserike Rd, Accord, NY 12404 Phone: 845-687-2400 Fax: 845-687-7109 | |
Faith Johnson, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 500 Queens Hwy, Accord, NY 12404 Phone: 845-705-4783 | |
Mrs. Lucille Marie Vansickle, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 122 Kyserike Rd, Accord, NY 12404 Phone: 845-687-2400 Fax: 845-687-7665 | |
Mrs. Christine Oakley, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 301 Granite Rd, Accord, NY 12404 Phone: 845-626-1069 | |
Joann Redmond, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 122 Kyserike Rd, Accord, NY 12404 Phone: 845-687-2400 Fax: 845-687-8980 |